ActiveSite Pharmaceuticals

Home

Home

Technology

Clinical Indications

Plasma Kallikrein

Founders

Publications & News

Contact Us

ActiveSite Pharmaceuticals utilizes proprietary lead discovery technology to discover new small molecule drug candidates for human diseases with unmet medical need. Our initial efforts are focused on developing novel, innovative treatments for the major vision-threatening complication of diabetes, diabetic macular edema, and the genetic disease hereditary angioedema, by targeting the vascular protease plasma kallikrein.

Technology

Clinical Indications

Plasma Kallikrein

Founders

Publications & News

Contact Us


  Copyright 2015 ActiveSite Pharmaceuticals, Inc.